Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Heise

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Science (New York, N.Y.)|October 18, 1996
An adenovirus mutant that replicates selectively in p53-deficient human tumor cellsJ R Bischoff, D H Kirn, A Williams, et al.
British Journal of Haematology|August 14, 2012
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differencesHeather E Eve, Sean Carey, Sarah J Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancerI Ganly, D Kirn, G Eckhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in miceXiaohua Xin, Tinya J Abrams, Paul W Hollenbach, et al.
Nature Medicine|August 10, 2000
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancerF R Khuri, J Nemunaitis, I Ganly, et al.
Journal of Medicinal Chemistry|December 31, 2008
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitorsPaul A Renhowe, Sabina Pecchi, Cynthia M Shafer, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Science (New York, N.Y.)|October 18, 1996
An adenovirus mutant that replicates selectively in p53-deficient human tumor cellsJ R Bischoff, D H Kirn, A Williams, et al.
British Journal of Haematology|August 14, 2012
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differencesHeather E Eve, Sean Carey, Sarah J Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancerI Ganly, D Kirn, G Eckhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in miceXiaohua Xin, Tinya J Abrams, Paul W Hollenbach, et al.
Nature Medicine|August 10, 2000
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancerF R Khuri, J Nemunaitis, I Ganly, et al.
Journal of Medicinal Chemistry|December 31, 2008
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitorsPaul A Renhowe, Sabina Pecchi, Cynthia M Shafer, et al.
Pageof 4